Less than two weeks into Jesper Høiland’s new role as president of Novo Nordisk Inc. USA, the unthinkable happened.
What will be the consequences should more investors such as Martin Shkreli and Kyle Bass decide they want to play biopharma CEO for a day?
Since enactment of Obamacare, Republicans had vowed to “repeal and replace” the law. What has happened to the “replace” part of the “repeal and replace” of Obamacare?
The Toyota production system (TPS) has become popular in the biopharmaceutical industry for managing new product development and manufacturing. But there are some who question the effectiveness of this management approach for life sciences executives.
Leesa Gentry, Otsuka’s director of global clinical management, discusses the challenges of working on trials for MDR-TB, defined by its resistance to two main drugs currently used to treat TB – isoniazid (INH) and rifampicin (RMP).
New research from the Tufts Center for the Study of Drug Development (Tufts CSDD) discusses more accurate metrics of emerging outsourcing areas that can aid sponsor companies in strategic planning and resource planning.
The president of Novo Nordisk USA., Jesper Høiland, has worked in dozens of countries over the years. When asked what was the most important leadership lesson he’s learned that benefitted him most in his current role, he says...
Holding up three fingers Jesper Høiland’s, the president of Novo Nordisk, says, “The advice I give to every person considering working abroad or in another environment is that they have to address these three things.
Corporate Social Responsibility (i.e., being a good corporate citizen) has been a best business practice since the 1950s. For the biopharmaceutical industry, recent events, such as the drug pricing scandal involving Martin Shkreli, have once again brought CSR into the spotlight.
In November 2015, the Harvard Business Review (HBR) announced the top 100 CEOs in the world. Though the list included household names like Starbucks (12), Nike (21), and Amazon (87), what is even more interesting than the fact that Novo Nordisk’s Lars Rebien Sørensen was ranked number one, was the healthcare industry as a whole had 13 CEOs in the top 100 — tying it for first with financial service (see Table 1). But if you dig even deeper, prepare for another surprise.
Last November, lawmakers and the Obama administration began ratcheting up efforts targeted at pharmaceutical company’s “high-priced drugs.” Some view this as a sign that legislators are trying to bridge the political divide to tackle a key driver of rising healthcare costs. But are high-priced drugs and biopharmaceutical companies the most important driver to target? After all, research has shown that hospitals and physicians are much bigger contributors to overall U.S. healthcare spend. Further, when compared to the rest of the word, U.S. citizens are the top consumers of expensive sophisticated diagnostic imaging technologies, pay nearly twice as much as other countries for hospital and physician procedures and services, yet have the worst health outcomes compared to their international peers. In fact, if we look at the nine drivers behind high U.S. healthcare costs, there seems to be numerous opportunities for improvement — in addition to trying to reduce the price we pay for medicines. So why then is it Americans heap a disproportionate amount of the blame for staggering healthcare costs on the biopharmaceutical industry? Could it be drug-price sticker shock? Let’s explore.
Unfortunately, a minor mechanical issue involving one of my flights caused me to arrive a day late for the 34th Annual J.P. Morgan Healthcare Conference (JPM) in San Francisco (January 11-14). While missing Monday at one of biopharma’s biggest annual events (Twitter hashtag #JPM16) translates to a huge lost opportunity (i.e., not being able to attend 16 of 108 scheduled presentations/breakout sessions), when it comes to JPM, one day does not a conference make. Despite having one less day to work with, and splitting time between JPM, the 2016 Biotech Showcase (BTS), and the Redefining Early Stage Investments (RESI) conference, San Francisco + JPM in January always seems to provide for a few surprises.